Lv1
18 积分 2025-09-29 加入
Glycosylation in cancer: mechanisms, diagnostic markers, and therapeutic applications
9小时前
已完结
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
21天前
已完结
Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies
21天前
已完结
Complete Response to Lorlatinib in Lung Adenocarcinoma With EML4-ALK Fusion Variant (E6;A18): Case Report and Literature Review
1个月前
已完结
SMARCA4-deficient Non-small Cell Lung Carcinoma Harboring ALK Fusion
1个月前
已完结
Targeting DNA Topoisomerase I for the Treatment of Cancer: Past, Present and Future
1个月前
已完结
Bystander effect in antibody-drug conjugates: Navigating the fine line in tumor heterogeneity
1个月前
已完结
Mechanisms of resistance to antibody–drug conjugates in cancers
1个月前
已完结
p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2+ breast cancer that limits trastuzumab deruxtecan efficacy
1个月前
已完结
皖公网安备34019202002308
